Zobrazeno 1 - 10
of 208
pro vyhledávání: '"JoAnne M, Foody"'
Autor:
Ezra A. Amsterdam, MD, JoAnne M. Foody, MD, FACC, FAHA, C. Tissa Kappagoda, MD, PhD, Philip R. Liebson, MD
Despite recent advances in diagnosis and management of cardiovascular disease, risk factors for CVD are still underrecognized in many special populations. Increased awareness is needed to better prevent, diagnose and manage CVD in women, Hispanics, A
Autor:
Mary Norine Walsh, James A. Arrighi, Joseph G. Cacchione, Anna Lisa Chamis, Pamela S. Douglas, Claire S. Duvernoy, JoAnne M. Foody, Sharonne N. Hayes, Dipti Itchhaporia, Michael S. Parmacek, Ada C. Stefanescu Schmidt, George W. Vetrovec, Thad F. Waites, John J. Warner
Publikováno v:
Journal of the American College of Cardiology. 80:2135-2155
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4319ba71c1dda9d075badba4046848e2
https://doi.org/10.1016/j.jacc.2022.08.748
https://doi.org/10.1016/j.jacc.2022.08.748
Autor:
John W. Eikelboom, Deepak L. Bhatt, Scott D. Berkowitz, Jackie Bosch, Tamara Marsden, Derek L Connolly, Kelley R. Branch, Dragos Vinereanu, Keith A.A. Fox, Kevin R. Bainey, Jeffrey L. Probstfield, Petr Widimsky, Robert C. Welsh, Salim Yusuf, Basil S. Lewis, Rafael Diaz, Stuart J. Connolly, Eva Muehlhofer, P. Gabriel Steg, JoAnne M. Foody
Publikováno v:
Circulation. 141:1141-1151
Background: The COMPASS trial (Cardiovascular Outcomes for People using Anticoagulation Strategies) demonstrated that dual pathway inhibition (DPI) with rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily versus aspirin 100 mg once daily re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37d621ff8f5cdbf167a85451b4224d23
https://doi.org/10.1161/circulationaha.119.044598
https://doi.org/10.1161/circulationaha.119.044598
Autor:
JoAnne M. Foody
Publikováno v:
Clinical Interventions in Aging
Non-valvular atrial fibrillation (NVAF) significantly contributes to the burden of stroke, particularly in elderly patients. The challenge of optimizing anticoagulation therapy is balancing efficacy and bleeding risk, especially as the same patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04b9c0bd8c2bc57c49323c7fcc8fcd46
https://doi.org/10.2147/cia.s111216
https://doi.org/10.2147/cia.s111216
Autor:
Robert P. Giugliano, Dylan L. Steen, Robert J. Sanchez, JoAnne M. Foody, Laura Becker, Irfan Khan, Katherine Gorcyca
Publikováno v:
Clinical Cardiology. 40:155-162
Background Lowering low-density lipoprotein cholesterol with statins reduces risk of cardiovascular events. We examined patterns and predictors of filled prescriptions for lipid-lowering therapy (LLT) in subgroups of patients with atherosclerotic car
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::72878f789b0b3d6af93d8d1b3668d84d
https://doi.org/10.1002/clc.22641
https://doi.org/10.1002/clc.22641
Autor:
JoAnne M. Foody, Fatima Rodriguez
Publikováno v:
DeckerMed Medicine.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10563ff32b9ee6e70c1d0773a01571fd
https://doi.org/10.2310/im.1031
https://doi.org/10.2310/im.1031
Publikováno v:
Journal of Clinical Lipidology. 10:472-489
Cardiovascular (CV) disease is a leading cause of death worldwide, accounting for approximately 31.4% of deaths globally in 2012. It is estimated that, from 1980 to 2000, reduction in total cholesterol accounted for a 33% decrease in coronary heart d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd24f8cce6c857ecff777eee9ad829a7
https://doi.org/10.1016/j.jacl.2015.11.010
https://doi.org/10.1016/j.jacl.2015.11.010
Autor:
JoAnne M. Foody, W. Virgil Brown, Franklin J. Zieve, Andrew M. Tershakovec, Arvind Shah, Joanne E. Tomassini
Publikováno v:
Journal of Clinical Lipidology. 10:116-123
Background Little is known regarding relationships between high-sensitivity C-reactive protein (hsCRP) and lipoproteins other than low-density lipoprotein cholesterol (LDL-C). High-density lipoprotein (HDL), with both anti-inflammatory and cholestero
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f63ed2296fda645c0f35013599ec4b3
https://doi.org/10.1016/j.jacl.2015.10.002
https://doi.org/10.1016/j.jacl.2015.10.002
Autor:
Howard S. Friedman, Kim Heithoff, JoAnne M. Foody, Prakash Navaratnam, Temitope Olufade, Fatima Rodriguez
Publikováno v:
The American Journal of Cardiology. 115:190-195
We examined trends in low-density lipoprotein cholesterol (LDL-C) goal attainment in high-risk patients and use of high-potency statins (HPS) in a large, managed-care database from 2004 to 2012. The 2013 American Heart Association/American College of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1180a6de59fbe0a022f850c288fa241
https://doi.org/10.1016/j.amjcard.2014.10.021
https://doi.org/10.1016/j.amjcard.2014.10.021
Autor:
Mikhail Kosiborod, John A. Spertus, John F. Beltrame, JoAnne M. Foody, Suzanne V. Arnold, Anna Grodzinsky, Susmita Parashar, Kensey Gosch, Thomas M. Maddox
Publikováno v:
European heart journal. Quality of careclinical outcomes. 1(2)
Aims Myocardial infarction (MI) patients without obstructive coronary artery disease (CAD) are at increased risk for recurrent ischaemic events, but angina frequency post-MI has not been described. Methods and results Among MI patients who underwent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4965d24fcd62cfcf52e0ada3466816da
https://pubmed.ncbi.nlm.nih.gov/28239487
https://pubmed.ncbi.nlm.nih.gov/28239487